J&J CEO Joaquin Duato on cancer treatments, M&A outlook and 'most favored nation' policy
CNBC’s Angelica Peebles and Johnson & Johnson chairman and CEO Joaquin Duato join 'Squawk Box' to discuss the company's 5-year multiple myeloma treatment study, the company's cancer treatments, M&A outlook, 'most favored nation' pricing, and more.
▶︎
Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC
▶︎
Inside the Johnson & Johnson Baby Powder Controversy | Bloomberg Investigates
▶︎
J&J CEO Joaquin Duato on Q3 results: We are entering an era of accelerated growth
▶︎
Leading the Charge: CEOs Navigating Business Transformation | Global Conference 2025
▶︎
Johnson & Johnson Our History, Our Mission
▶︎
In Billionaires We Trust: $90B Pharma Collapse
▶︎
Netanyahu says Israel 'not a party' to U.S.-Iran memorandum of understanding as Trump touts deal
▶︎
My Golden Retriever Heals a Terrified Rescue Kitten in Just 3 Meetings!
▶︎
Why Everything Is So Expensive - Financial Expert Patrick Boyle Explains
▶︎
Nobody Breaks Celebrities Like Rowan Atkinson
▶︎
CNBC Morning Call Panel Tuesday, May 19, 2026
▶︎
CEO DIALOGUE #7 - Pascal Soriot, AstraZeneca
▶︎
Watch Jim Cramer's interview with Johnson & Johnson CEO Joaquin Duato
▶︎
The CIA Sent Him to Prison. Now He's Speaking Out
▶︎
Bill Ackman: Here's What the Market is MISSING
▶︎
A Conversation with Nvidia CEO Jensen Huang | Global Conference 2025
▶︎
'CANCER OCCURRED near injection sites...': Bombshell testimony ‘EXPOSES’ COVID-19 vaccine injuries
▶︎
Johnson & Johnson CEO: 'We’re in the Golden Era of Medical Innovation'
▶︎
Trump "Loves" Inflation and Lies About "No Wars," Fox News Criticizes His Iran Claims: A Closer Look
▶︎